ストックスクリーナーアプリを入手
2.77
2.81%
-0.08
前日終値:
$2.85
開ける：
$2.88
24時間の取引高:
71,446
Relative Volume:
0.38
時価総額：
$124.21M
収益：
$8,000
当期純損益:
$-32.15M
株価収益率:
-3.1986
EPS:
-0.866
ネットキャッシュフロー:
$-26.37M
1週間 パフォーマンス:
+9.49%
1か月 パフォーマンス:
+7.78%
6か月 パフォーマンス:
-64.67%
1年 パフォーマンス:
+10.36%
1日の値動き範囲:
$2.72
$2.9692
1週間の範囲:
$2.46
$2.97
52週間の値動き範囲:
$2.255
$8.535
Genelux Corp Stock (GNLX) Company Profile
名前
Genelux Corp
セクター
電話
805-267-9889
住所
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.77 | 127.80M | 8,000 | -32.15M | -26.37M | -0.866 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Lake Street | Buy |
| 2024-10-29 | 開始されました | Guggenheim | Buy |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-11-27 | 開始されました | H.C. Wainwright | Buy |
| 2023-09-12 | 開始されました | Maxim Group | Buy |
| 2023-02-15 | 開始されました | The Benchmark Company | Speculative Buy |
すべてを表示
Genelux Corp (GNLX) 最新ニュース
GNLX SEC FilingsGenelux Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Genelux Corp expected to post a loss of 18 cents a shareEarnings Preview - TradingView
[ARS] GENELUX Corp SEC Filing - Stock Titan
Genelux (NASDAQ: GNLX) details 2026 virtual meeting, board and auditor votes - Stock Titan
Genelux (GNLX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
GNLX Technical Analysis | Trend, Signals & Chart Patterns | GENELUX CORP (NASDAQ:GNLX) - ChartMill
Olvi Vec could reshape advanced ovarian cancer treatment, Genelux claims - Traders Union
Genelux advances next generation oncolytic immunotherapies for cancer treatment - Traders Union
Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - MarketBeat
Is Genelux Corporation (GNLX) Stock Good for Short Term | Price at $2.45, Down 7.20%Elite Trading Signals - Newser
GNLX Stock Analysis: Genelux Corporation Holds Near 2.57 Level With Modest Daily Gain - Newser
GNLX Technical Analysis & Stock Price Forecast - Intellectia AI
Analyst Calls: Can Genelux Corporation outperform in the next rally2026 Market Outlook & AI Driven Price Predictions - baoquankhu1.vn
GNLX PE Ratio & Valuation, Is GNLX Overvalued - Intellectia AI
Genelux head of regulatory sells $1.4k in shares By Investing.com - Investing.com Australia
Yu Yong, Genelux SVP, sells $2192 in GNLX stock By Investing.com - in.investing.com
Genelux CEO Zindrick sells $8668 in shares By Investing.com - Investing.com South Africa
Genelux head of regulatory sells $1.4k in shares - investing.com
Cappello, Genelux CTO, sells $2192 in GNLX stock By Investing.com - Investing.com South Africa
Yu Yong, Genelux SVP, sells $2192 in GNLX stock - Investing.com
Genelux CEO Zindrick sells $8668 in shares - Investing.com
Genelux (GNLX) Head of Regulatory sells 585 shares to cover RSU taxes - Stock Titan
[Form 4] GENELUX Corp Insider Trading Activity - Stock Titan
Genelux (NASDAQ: GNLX) SVP sells 906 shares to cover RSU taxes - Stock Titan
Genelux (GNLX) CEO sells shares to cover RSU tax obligations - Stock Titan
AI Stocks: Is Genelux Corporation showing insider buyingShort Setup & Technical Pattern Alert System - baoquankhu1.vn
FY2029 Earnings Estimate for Genelux Issued By HC Wainwright - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Genelux (NASDAQ:GNLX) Price Target Cut to $20.00 by Analysts at Benchmark - MarketBeat
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside - TipRanks
Genelux Corp 2024 Annual Report: Oncolytic Virus Pipeline, Olvi-Vec Clinical Trials, Strategy, Risks, and Competitive Landscape 66686970719293 - Minichart
Gap Down: Can Genelux Corporation be recession proof2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Genelux (NASDAQ: GNLX) launches $100M at-the-market program with TD Cowen - Stock Titan
Genelux Establishes $100 Million At-The-Market Equity Program - TipRanks
Genelux Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Genelux Establishes $100 Million ATM Equity Program With TD Cowen - TradingView
Genelux (NASDAQ: GNLX) launches $100M at-the-market stock plan - stocktitan.net
Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership Appointment - Quiver Quantitative
[10-K] GENELUX Corp Files Annual Report | GNLX SEC FilingForm 10-K - Stock Titan
GENELUX 2025 10-K: Revenue $0.01M, Net Loss $32.1M - tradingview.com
Cancer drug readout nears as Genelux says cash lasts into 2027 - Stock Titan
Aug Analyst Calls: What is the long term forecast for Genelux Corporation stockMarket Trend Review & Free Verified High Yield Trade Plans - baoquankhu1.vn
Genelux Corp. (GNLX) Gets a Buy from Maxim Group - The Globe and Mail
Genelux Corp expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Insider Sell: John Thomas Sells 10,000 Shares of Genelux Corp (G - GuruFocus
Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 10,000 Shares of Stock - MarketBeat
[144] GENELUX Corp SEC Filing - Stock Titan
GNLX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Genelux Corp (GNLX) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):